195 related articles for article (PubMed ID: 15867239)
1. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP
Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
Xu L; Eiseman JL; Egorin MJ; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):185-219. PubMed ID: 14571691
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Tse AN; Klimstra DS; Gonen M; Shah M; Sheikh T; Sikorski R; Carvajal R; Mui J; Tipian C; O'Reilly E; Chung K; Maki R; Lefkowitz R; Brown K; Manova-Todorova K; Wu N; Egorin MJ; Kelsen D; Schwartz GK
Clin Cancer Res; 2008 Oct; 14(20):6704-11. PubMed ID: 18927314
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
Ramanathan RK; Egorin MJ; Erlichman C; Remick SC; Ramalingam SS; Naret C; Holleran JL; TenEyck CJ; Ivy SP; Belani CP
J Clin Oncol; 2010 Mar; 28(9):1520-6. PubMed ID: 20177028
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Goetz MP; Toft D; Reid J; Ames M; Stensgard B; Safgren S; Adjei AA; Sloan J; Atherton P; Vasile V; Salazaar S; Adjei A; Croghan G; Erlichman C
J Clin Oncol; 2005 Feb; 23(6):1078-87. PubMed ID: 15718306
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
Grem JL; Morrison G; Guo XD; Agnew E; Takimoto CH; Thomas R; Szabo E; Grochow L; Grollman F; Hamilton JM; Neckers L; Wilson RH
J Clin Oncol; 2005 Mar; 23(9):1885-93. PubMed ID: 15774780
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
16. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
[TBL] [Abstract][Full Text] [Related]
17. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
[TBL] [Abstract][Full Text] [Related]
18. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
19. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
Banerji U; O'Donnell A; Scurr M; Pacey S; Stapleton S; Asad Y; Simmons L; Maloney A; Raynaud F; Campbell M; Walton M; Lakhani S; Kaye S; Workman P; Judson I
J Clin Oncol; 2005 Jun; 23(18):4152-61. PubMed ID: 15961763
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
